IMO-2055, a TLR9 agonist, is in clinical development for the treatment of cancer.

In December 2007, Idera entered into an exclusive, worldwide licensing and collaboration agreement with Merck KGaA for the research, development, and commercialization of Idera's TLR9 agonists, including IMO-2055, for the treatment of cancer, excluding vaccines. (Press Release) Merck KGaA refers to IMO-2055 as EMD 1201081.

Merck KGaA is conducting a Phase 2 clinical trial of IMO-2055, in combination with cetuximab (Erbitux®) in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (Press Release)

In July 2011, Idera provided an update on Merck KGaA's clinical development of IMO-2055. (Press Release)

Prior Clinical Trials conducted by Idera of IMO-2055

• IMO-2055 Phase 2 Stage A Clinical Trial in Renal Cell Carcinoma (Press Release)
• IMO-2055 Phase 1 Clinical Trial in Combination with Gemzar^® and Camptosar^® in Refractory Solid Tumor Cancer Patients (Press Release)
• IMO-2055 Phase 1 Clinical Trial in Refractory Solid Tumor Cancer Patients
• IMO-2055 Phase 1 Clinical Trial in Healthy Subjects

Presentations

• Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma. Eighth International Kidney Cancer Symposium; September 2009
  (Presentation)
  
• Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva^® and Avastin^® in Non-Small Cell Lung Cancer. 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO); Abstract number 9.148; September 2009
  (Presentation)